| abstract |
The invention relates to compounds of the general formula (I) wherein R1 is lower alkoxy, cycloalkyl or aryl, unsubstituted or substituted by halogen or lower alkoxy or is NR'R'', wherein R' and R'' are independently from each other hydrogen, lower alkyl, lower alkenyl, lower alkinyl, -(CR¿2?)n-aryl unsubstituted or substituted by one to three substituents, selected from the group, consisting of halogen or lower alkoxy, or are (CH2)n+1NR2, -(CH2)n-pyridinyl, -(CH2)n-indanyl, -(CH2)n-cycloalkyl, -(CH2)n-O-lower alkyl, -(CH2)n-C(O)-NR2, -(CH2)n-CF3, OR R' and R'' are together with the N atom to which they are attached pyrrolidin-1-yl, piperidin-1-yl, 3,4-dihydro-1H-isoquinolin-2-yl, morpholinyl, azatidin-1-yl, 3,6-dihydro-2H-pyridin-1-yl, thiomorpholinyl, 2,5-dihydro-pyrrol-1-yl, thiazolidin-3-yl, piperazinyl, azocan-1-yl, azepan-1-yl, octahydroquinolin-1-yl, octahydroquinolin-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, which rings may be unsubstituted or substituted by one to three substituents, selected from the group, consisting of lower alkyl, phenyl, benzyl, pyridyl, -C(O)-NR2, -(CH2)n-O-lower alkyl or NR-C(O)-lower alkyl; R?2¿ is aryl or a 5 or 6 membered heteroaryl group, which rings are unsubstituted or substituted by lower alkyl, halogen, hydroxy or lower alkoxy; X is a bond or N(R)CH¿2?-; R is hydrogen or lower alkyl; N is 0,1,2,3,4,5 or 6; and to their pharmaceutically acceptable salts. The compounds have a good affinity to the adenosin receptor and may therefore be used in the treatment of diseases, related to this receptor. |